Radioimmunotherapy

Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo

CHICAGO, According to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings, patients treated for follicular lymphoma, a slow-growing type of non-H...

A New Option For AIDS Treatment - Radioimmunotherapy

Radioimmunotherapy is a technique used in treating cancer , in which antibodies which have radioactive isotopes attached to them are injected into patients.// These antibodies target and destroy cancer cells inside the body , by delivering the radioactive particles . The main advatage of this tre...

Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma

...ocal disease. However, EBRT does not address systemic sites of involvement in OAL in patients with multifocal disease and therefore, systemic targeted radioimmunotherapy with Zevalin might offer an alternative to treating OAL. "This study demonstrates the potential for Zevalin to provide an alternative to EBRT, ...

Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals

... a decision regarding the sBLA in early April, 2009. About Zevalin(R) Zevalin (R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymph...

Zevalin Data to be Presented at ASH 2008

...008 5:30-7:30 PM 1144 Poster I-249 radioimmunotherapy (90Y- ...008 6:00-8:00 PM 1959 Poster II-53 radioimmunotherapy with ...ted radioimmunotherapy with ...

New study shows potential to treat or prevent viral cancers

...esented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel opti... of the study, Viral Antigens as Novel Targets for radioimmunotherapy of Viral Cancers. "The magnitude and global health...ine, who collaborates with Dadachova on developing radioimmunotherapy of infectious diseases and cancers. The study invo...

Every patient is unique: Individualized therapies for non-Hodgkin's lymphoma

... important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at SNM's 55th Annual Meeting. PET imaging allows practitioners t...

Einstein-Montefiore Center for AIDS Research receives $8.5M award from NIH

...eing the first in the world to identify pediatric AIDS as a distinct disease and to establish a day-care center for children with AIDS; identifying radioimmunotherapy (RIT) as a possible therapy for preventing or treating HIV infection; developing a vaccine to combat extremely drug resistant tuberculosis (XDR-TB)...

Radioimmunotherapy After Chemo Safe for Common Lymphoma

... THURSDAY, March 13 (HealthDay News) -- radioimmunotherapy after chemotherapy is safe and effective for patie...), according to an Italian study. It found that radioimmunotherapy with the radioactive drug yttrium-90 (90Y) ibritum...tial response) were deemed eligible for subsequent radioimmunotherapy with 90Y- ibritumombab tiuxetan. After that treatm...

USC researchers find benefit for lymphoma patients in combined PET-CT scanning

...advantage of combined PET-CT imaging in evaluating radioimmunotherapy for patients with non-Hodgkin lymphoma, says Gary ...aken for active cancer when CT is used alone." radioimmunotherapy is a type of radiation treatment that targets canc...both several weeks before and several months after radioimmunotherapy for non-Hodgkin lymphoma. After evaluation of CT i...

Radioimmunotherapy in Medical Technology

Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma

Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results published in Journal of Clinical Oncology SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the...

Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases

- Initial Phase II Study Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced th...

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study

- Results Presented at the 12th Congress of European Hematology Association (EHA) - VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that...

Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma

...TIC) markets Zevalin in the United States. "In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an inte...

Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma

... Phase II study of investigational regimen demonstrates important role of radioimmunotherapy in converting partial remissions to complete remissions and indu...treatment of follicular NHL. "This study underscores the potential use of radioimmunotherapy with Zevalin to convert the majority of partial remissions to complete remi...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

...TI) (Nasdaq: CTIC ; MTAX) announced today that results of a phase II clinical study, published in the journal CANCER demonstrate that the addition of radioimmunotherapy (RIT) to chemotherapy for previously untreated patients with non-follicular indolent non-Hodgkin's lymphoma (NHL) was both well tolerated and effectiv...

Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma

... Results underscore promise of radioimmunotherapy in ASCT and warrant ran...Clinical Oncology demonstrate that the addition of radioimmunotherapy (RIT) to high-dose chemotherapy (HDC) followed by ... receive TBI as part of their preparative regimen. radioimmunotherapy with Zevalin(R) (Ibritumomab Tiuxetan), approved f...

8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar

... follicular lymphoma: update/results after a median follow up of 8 years, presented at ASCO 2007 annual meeting. 2. Bierman et al. abstract #8013 -- radioimmunotherapy with 131-I tositumomab enhances survival in good prognosis relapsed and high risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose c...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

...reatment is not expected to offer clinical benefit. Based on this Phase I experience, combined/sequential treatment with chemotherapy and fractionated radioimmunotherapy is being considered for future trials," commented Dr. Gulec. "We have presented these preliminary results to the FDA and are in discussion with the ...

Radioimmunotherapy in Biological News

Einstein researchers demonstrate a novel approach to treating AIDS

...IDS. "This study in mice supports the idea that radioimmunotherapy might help in treating people infected with HIV," ...s the cell to which that protein is attached. radioimmunotherapy is an accepted treatment for several types of canc...adachova and her colleagues have successfully used radioimmunotherapy against a variety of disease-causing microbes­firs...

New Treatment Rivals Chemotherapy For Lymphoma, Study Finds

...ernal medicine at the U-M Medical School. "New studies can now be designed to begin to test this possibility," he adds. Previous stories : - New radioimmunotherapy Drug Proves Highly Effective For Killing Off B Cell Non-Hodgkin's Lymphoma - Newly Approved Therapy Successfully Targets Non-Hodgkin's Lymphoma -...

Radioimmunotherapy in Biological Technology

Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma

CHICAGO, June 2 /PRNewswire-FirstCall/ -- At the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), two studies were presented investigating the potential utility of Zevalin(R) (Ibritumomab Tiuxetan) radioimmunotherapy as replacement for external beam radiations or supple...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

... to promptly satisfy all of the closing conditions. About Zevalin(R) Zevalin (R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymph...

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review

...te of April 2, 2009 has been established by the FDA for a decision regarding the approval of the Zevalin sBLA. If approved, Zevalin would be the first radioimmunotherapy available to patients as first-line consolidation therapy. It is estimated that there would be approximately 18,000 additional patients that currently...

High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma

...ative treatments, was absent, and all patients were able to maintain normal oral intake of food and water. The excellent tolerability of myeloablative radioimmunotherapy was noteworthy in that 19 patients (63 percent) had previously not met the eligibility criteria for chemotherapy- based autotransplantation regimens a...

Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy

... Approval would make Zevalin only radioimmunotherapy in U.S. to be Indicated for Use in First-Line Therapy ...h follicular non-Hodgkin's lymphoma. If approved, Zevalin would be the only radioimmunotherapy in the U.S. with approval for use as first-line consolidation therapy. The ...

Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma

...ponses," said James A. Bianco, M.D., President and CEO of CTI. "The results of the study suggest that addition of MGd may enhance the effectiveness of radioimmunotherapy with Zevalin. Further studies using this combination in patients with follicular or diffuse large B-cell lymphoma are warranted." About the Study ...

Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008

...arket of more than 10,000 patients in the Unites States," noted Bianco. "With new compelling clinical data, coupled with our focus on making Zevalin radioimmunotherapy readily available for medical oncologists to administer to patients in their clinics, we believe a significantly higher response rate is achievable wi...

Vical Names Andrew de Guttadauro Vice President, Corporate Development

...trategy at Biogen Idec since February 2007, following a two-year assignment overseeing the commercial development of that company's Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, where he directed marketing efforts f...